Dr Benedetta Arno

Benedetta leads the design, planning, and execution of imaging-driven preclinical programs, delivering high-quality data packages to support biotech and pharmaceutical collaborators.

With deep expertise in molecular and optical imaging techniques, including PET, SPECT, CT, and IVIS, she manages a team of scientists dedicated to investigating the biodistribution, pharmacokinetics, and efficacy of radiopharmaceuticals and other therapeutic modalities.

Holding an MSc in Biomedical Science and a PhD in Molecular Medicine, as well as extensive experience across in vitro, in vivo, and ex vivo studies, she drives innovation through multiple stages of drug discovery and works closely with MDC partners to continuously develop and expand new scientific capabilities.

Dr Juliana Maynard

Juliana Maynard is an expert Imaging Scientist specialising in pre-clinical imaging technologies, which ultimately aims to advance innovative drug discovery, bringing medicines to patients, faster.

An enthusiastic, proactive, very committed and hard-working individual Juliana has worked with a broad range of imaging modalities including PET, SPECT, CT, ultrasound and MRI. She has a proven track record of research as evidenced in her publications across a wide range of disease and therapy areas.

She possesses good project management skills and has successfully delivered multiple projects with a strong delivery focus. She enjoys working across boundaries using her interpersonal skills to engage with customers and to “put an idea” into practice. Juliana has been based in the North West since earning her PhD at the University of Edinburgh in 2006.

She worked at the University of Manchester and then spent 9 years in increasingly senior roles at AstraZeneca. On leaving AstraZeneca, Juliana recognised the opportunity that medical imaging can have in improving and accelerating drug discovery and set up the creation of a commercial imaging service offering with the ambition to make this readily available for use across the UK drug discovery community.